Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib and Sapanisertib in Advanced Solid Tumors and TNBC
NCT02719691Phase 1Completed
- Sponsor
- University of Colorado Denver
- Start
- May 2016
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sapanisertib and alisertib in solid tumor, triple-negative breast cancer (TNBC) and pancreatic adenocarcinoma (PDAC) (7 arms), sponsored by University of Colorado Denver. Primary endpoint: Maximum Tolerated Dose at 28 days. Started May 2016; status: completed.
02
Drugs
sapanisertibalisertib
03
Conditions
solid tumortriple-negative breast cancer (TNBC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02719691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02719691.